ABIOMED, Inc. with ticker code (ABMD) have now 6 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 300 and 215 calculating the mean target price we have 248.33. With the stocks previous close at 216.79 this would indicate that there is a potential upside of 14.5%. The 50 day moving average now sits at 179.33 and the 200 day MA is 225.8. The company has a market cap of $9,577m. Visit the company website at: http://www.abiomed.com
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company engages in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.